BridgeBio Pharma, Inc. $BBIO Shares Acquired by Janus Henderson Group PLC

Janus Henderson Group PLC grew its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 25.8% during the fourth quarter, HoldingsChannel reports. The firm owned 11,000,457 shares of the company’s stock after purchasing an additional 2,259,378 shares during the quarter. Janus Henderson Group PLC owned about 0.06% of BridgeBio Pharma worth $841,349,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Commonwealth Equity Services LLC grew its holdings in shares of BridgeBio Pharma by 4.9% in the 4th quarter. Commonwealth Equity Services LLC now owns 5,179 shares of the company’s stock worth $396,000 after acquiring an additional 244 shares during the period. Farther Finance Advisors LLC lifted its stake in shares of BridgeBio Pharma by 91.4% during the 4th quarter. Farther Finance Advisors LLC now owns 513 shares of the company’s stock worth $39,000 after purchasing an additional 245 shares during the period. State of New Jersey Common Pension Fund D lifted its stake in shares of BridgeBio Pharma by 0.5% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 51,896 shares of the company’s stock worth $3,970,000 after purchasing an additional 246 shares during the period. CWM LLC lifted its stake in shares of BridgeBio Pharma by 4.3% during the 4th quarter. CWM LLC now owns 6,444 shares of the company’s stock worth $493,000 after purchasing an additional 265 shares during the period. Finally, Xponance LLC lifted its stake in shares of BridgeBio Pharma by 2.2% during the 4th quarter. Xponance LLC now owns 12,536 shares of the company’s stock worth $959,000 after purchasing an additional 272 shares during the period. Institutional investors and hedge funds own 99.85% of the company’s stock.

BridgeBio Pharma Stock Up 1.1%

Shares of NASDAQ:BBIO opened at $67.39 on Thursday. The firm has a fifty day moving average of $69.89 and a two-hundred day moving average of $72.04. The firm has a market capitalization of $13.20 billion, a P/E ratio of -18.02 and a beta of 0.97. BridgeBio Pharma, Inc. has a 12-month low of $39.65 and a 12-month high of $84.94.

BridgeBio Pharma (NASDAQ:BBIO) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.14). The company had revenue of $194.52 million for the quarter, compared to analyst estimates of $178.07 million. During the same period in the previous year, the firm posted ($0.88) earnings per share. The company’s revenue was up 66.8% compared to the same quarter last year. Equities research analysts expect that BridgeBio Pharma, Inc. will post -2.32 earnings per share for the current fiscal year.

Analysts Set New Price Targets

BBIO has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and set a $110.00 price target on shares of BridgeBio Pharma in a research note on Thursday, May 28th. Citigroup assumed coverage on BridgeBio Pharma in a report on Tuesday, May 19th. They issued a “neutral” rating and a $82.00 price target for the company. Canaccord Genuity Group assumed coverage on BridgeBio Pharma in a research note on Wednesday, June 3rd. They set a “buy” rating and a $104.00 target price for the company. Morgan Stanley raised their target price on BridgeBio Pharma from $94.00 to $98.00 and gave the company an “overweight” rating in a research note on Thursday, May 28th. Finally, Royal Bank Of Canada started coverage on shares of BridgeBio Pharma in a research report on Thursday, April 9th. They set an “outperform” rating and a $100.00 price target on the stock. Twenty-two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, BridgeBio Pharma presently has a consensus rating of “Moderate Buy” and a consensus price target of $91.05.

Insider Activity at BridgeBio Pharma

In other news, CFO Thomas Trimarchi sold 13,651 shares of the business’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $65.08, for a total transaction of $888,407.08. Following the transaction, the chief financial officer owned 359,194 shares in the company, valued at approximately $23,376,345.52. The trade was a 3.66% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Randal W. Scott sold 10,000 shares of the company’s stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $67.15, for a total transaction of $671,500.00. Following the completion of the sale, the director directly owned 11,589 shares in the company, valued at approximately $778,201.35. The trade was a 46.32% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 261,994 shares of company stock worth $17,926,648. Insiders own 14.23% of the company’s stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.